Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Sherwood

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Lancet (London, England)|July 31, 2002
Is it clinically significant?Thomas Sherwood
Lancet (London, England)|February 25, 2003
Valgus or varus cello pathology?Thomas Sherwood
The Journal of Biological Chemistry|August 6, 2009
Identification of protein domains that control proton and calcium sensitivity of ASIC1aThomas Sherwood, Ruthie Franke, Shannon Conneely, et al.
Cancer|July 28, 2010
Quantitative HER2 protein levels predict outcome in fluorescence in situ hybridization-positive patients with metastatic breast cancer treated with trastuzumabAllan Lipton, Wolfgang J Köstler, Kim Leitzel, et al.
American Journal of Clinical Pathology|July 28, 2010
Comparison of central HER2 testing with quantitative total HER2 expression and HER2 homodimer measurements using a novel proximity-based assayWeidong Huang, Monica Reinholz, Jodi Weidler, et al.
Plos One|August 1, 2012
Correlation of HER2, p95HER2 and HER3 expression and treatment outcome of lapatinib plus capecitabine in her2-positive metastatic breast cancerSae-Won Han, Yongjun Cha, Agnes Paquet, et al.
Pathology Research International|December 15, 2010
Analytical Validation of a Highly Quantitative, Sensitive, Accurate, and Reproducible Assay (HERmark) for the Measurement of HER2 Total Protein and HER2 Homodimers in FFPE Breast Cancer Tumor SpecimensJeffrey S Larson, Laurie J Goodman, Yuping Tan, et al.
Nanomedicine : Nanotechnology, Biology, and Medicine|December 30, 2015
Deterministic transfection drives efficient nonviral reprogramming and uncovers reprogramming barriersDaniel Gallego-Perez, Jose J Otero, Catherine Czeisler, et al.
Breast Cancer Research and Treatment|August 21, 2013
HER3, p95HER2, and HER2 protein expression levels define multiple subtypes of HER2-positive metastatic breast cancerAllan Lipton, Laurie Goodman, Kim Leitzel, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Lancet (London, England)|July 31, 2002
Is it clinically significant?Thomas Sherwood
Lancet (London, England)|February 25, 2003
Valgus or varus cello pathology?Thomas Sherwood
The Journal of Biological Chemistry|August 6, 2009
Identification of protein domains that control proton and calcium sensitivity of ASIC1aThomas Sherwood, Ruthie Franke, Shannon Conneely, et al.
Cancer|July 28, 2010
Quantitative HER2 protein levels predict outcome in fluorescence in situ hybridization-positive patients with metastatic breast cancer treated with trastuzumabAllan Lipton, Wolfgang J Köstler, Kim Leitzel, et al.
American Journal of Clinical Pathology|July 28, 2010
Comparison of central HER2 testing with quantitative total HER2 expression and HER2 homodimer measurements using a novel proximity-based assayWeidong Huang, Monica Reinholz, Jodi Weidler, et al.
Plos One|August 1, 2012
Correlation of HER2, p95HER2 and HER3 expression and treatment outcome of lapatinib plus capecitabine in her2-positive metastatic breast cancerSae-Won Han, Yongjun Cha, Agnes Paquet, et al.
Pathology Research International|December 15, 2010
Analytical Validation of a Highly Quantitative, Sensitive, Accurate, and Reproducible Assay (HERmark) for the Measurement of HER2 Total Protein and HER2 Homodimers in FFPE Breast Cancer Tumor SpecimensJeffrey S Larson, Laurie J Goodman, Yuping Tan, et al.
Nanomedicine : Nanotechnology, Biology, and Medicine|December 30, 2015
Deterministic transfection drives efficient nonviral reprogramming and uncovers reprogramming barriersDaniel Gallego-Perez, Jose J Otero, Catherine Czeisler, et al.
Breast Cancer Research and Treatment|August 21, 2013
HER3, p95HER2, and HER2 protein expression levels define multiple subtypes of HER2-positive metastatic breast cancerAllan Lipton, Laurie Goodman, Kim Leitzel, et al.
Pageof 1